DoW Breast Cancer, Breakthrough Award Levels 1 and 2
Defense Health Agency Contracting Activity - DHACA
Free. Verify your email, then we send one reminder only.
- Posted
- Aug 20, 2026
- Closes
- Nov 18, 2026 (in 75 days)
Similar opportunities open now
- DoW Breast Cancer, Clinical Research Extension AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses in 75 days
- DoW Breast Cancer, Breakthrough Award Level 3Same funderOpenDefense Health Agency Contracting Activity - DHACACloses in 26 days
- DoW Breast Cancer, Breakthrough Award Level 4Same funderOpenDefense Health Agency Contracting Activity - DHACACloses in 26 days
- DoW Rare Cancers Concept AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses in 26 days
- DoW Duchenne Muscular Dystrophy, Clinical/Translational Research AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses in 14 days
Classification and identifiers
- Solicitation number
- HT942526BCRPBTA122
- Assistance listing (CFDA)
- 12.420
Amount
Amount not published by the funder
Who can apply
About this opportunity
Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Breakthrough Award mechanism supports promising research with high potential to lead to or make breakthroughs in breast cancer. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception. Applications must address the challenge in a way that can lead to a breakthrough and have major impact. The FY26 Breakthrough Award mechanism contains four different funding levels designed to support major (but not all) stages of research that will lead to clinical application. Each level specifies a distinct research scope. This program announcement discusses the Breakthrough Award Levels 1 and 2. Distinctive Features: * This funding mechanism allows for appl...